Table 2 The associations of IGF-1 concentrations with brain-related disorders

Dementia

 Q1

1,419

1.24 (1.18–1.31)

1.20 (1.11–1.30)

1.17 (1.08–1.26)

1.13 (1.05–1.22)

 Q2

1,144

1.00 (0.94–1.05)

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

 Q3

1,171

1.02 (0.96–1.08)

1.06 (0.97–1.15)

1.07 (0.99–1.16)

1.07 (0.99–1.16)

 Q4

1,123

0.98 (0.92–1.04)

1.07 (0.98–1.16)

1.09 (1.01–1.18)

1.08 (1.00–1.17)

Per 1-SD increment

 IGF-1 < 18 nmol/L

2,067

1.70 (1.63–1.78)

0.61 (0.55–0.67)

0.64 (0.58–0.71)

0.69 (0.62–0.77)

 IGF-1 ≥ 18 nmol/L

4,173

1.24 (1.21–1.28)

1.26 (1.17–1.35)

1.07 (1.02–1.12)

1.06 (1.01–1.11)

Stroke

 Q1

1,757

1.54 (1.47–1.62)

1.07 (1.00–1.15)

1.04 (0.98–1.12)

0.99 (0.93–1.06)

 Q2

1,618

1.41 (1.35–1.48)

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

 Q3

1,453

1.27 (1.21–1.34)

0.91 (0.85–0.98)

0.92 (0.86–0.99)

0.93 (0.87–1.00)

 Q4

1,412

1.24 (1.17–1.30)

0.91 (0.85–0.98)

0.92 (0.86–0.99)

0.94 (0.87–1.01)

Per 1-SD increment

 IGF-1 < 26 nmol/L

5,300

1.44 (1.40–1.48)

0.87 (0.83–0.90)

0.89 (0.86–0.92)

0.93 (0.90–0.97)

 IGF-1 ≥ 26 nmol/L

940

1.06 (0.99–1.13)

1.11 (1.03–1.18)

1.10 (1.03–1.18)

1.09 (1.02–1.17)

Parkinson's disease

 Q1

416

0.36 (0.33–0.40)

1.00 (Reference)

1.00 (Reference)

1.00 (Reference)

 Q2

478

0.41 (0.38–0.45)

1.17 (1.03–1.33)

1.18 (1.03–1.34)

1.20 (1.05–1.37)

 Q3

548

0.48 (0.44–0.52)

1.37 (1.21–1.56)

1.38 (1.21–1.57)

1.41 (1.24–1.60)

 Q4

674

0.59 (0.55–0.63)

1.74 (1.54–1.97)

1.76 (1.56–1.99)

1.78 (1.57–2.01)

 Per 1-SD increment

2,116

0.46 (0.44–0.48)

1.23 (1.18–1.27)

1.23 (1.18–1.28)

1.23 (1.18–1.28)